Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on DBV Technologies SA – American and keeping the price target at $19.00.

Sam Slutsky has given his Buy rating due to a combination of factors surrounding DBV Technologies’ promising developments with their VIASKIN Peanut treatment for children aged 4-7 with peanut allergies. The pivotal Phase 3 VITESSE trial has recently completed its final patient visit, and the topline data is expected before the end of the year. The trial aims to demonstrate a significant treatment response, which, if successful, could lead to accelerated approval and a BLA submission planned for the first half of 2026.
Slutsky is optimistic about the trial’s success due to its larger size compared to previous studies and several modifications that increase the likelihood of a positive outcome. The trial’s design improvements, such as changes in inclusion criteria and primary endpoints, are expected to enhance the chances of achieving statistical significance. This positive outlook, combined with the company’s financial positioning and upcoming milestones, underpins the Buy rating for DBV Technologies.